Comparison of Concert Pharmaceuticals Inc. (CNCE) and Sophiris Bio Inc. (NASDAQ:SPHS)

As Biotechnology businesses, Concert Pharmaceuticals Inc. (NASDAQ:CNCE) and Sophiris Bio Inc. (NASDAQ:SPHS), are affected by contrast. This especially applies to their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Concert Pharmaceuticals Inc. 10.50M 32.88 41.25M -1.77 0.00
Sophiris Bio Inc. N/A 0.00 16.26M -0.54 0.00

Table 1 shows gross revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 hightlights the return on equity, return on assets and net margins of the two companies.

Net Margins Return on Equity Return on Assets
Concert Pharmaceuticals Inc. -392.86% -20.8% -19%
Sophiris Bio Inc. 0.00% -946.2% -76.5%

Volatility and Risk

Concert Pharmaceuticals Inc. has a 0.94 beta, while its volatility is 6.00% which is less volatile than Standard & Poor’s 500. In other hand, Sophiris Bio Inc. has beta of 1.95 which is 95.00% more volatile than Standard & Poor’s 500.

Liquidity

Concert Pharmaceuticals Inc. has a Current Ratio of 26.7 and a Quick Ratio of 26.7. Competitively, Sophiris Bio Inc.’s Current Ratio is 4.2 and has 4.2 Quick Ratio. Concert Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Sophiris Bio Inc.

Analyst Ratings

Concert Pharmaceuticals Inc. and Sophiris Bio Inc. Recommendations and Ratings are available on the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Concert Pharmaceuticals Inc. 0 1 0 2.00
Sophiris Bio Inc. 0 0 0 0.00

Institutional & Insider Ownership

Institutional investors owned 75% of Concert Pharmaceuticals Inc. shares and 7.5% of Sophiris Bio Inc. shares. Insiders owned roughly 4.4% of Concert Pharmaceuticals Inc.’s shares. Competitively, Sophiris Bio Inc. has 0.75% of it’s share owned by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Concert Pharmaceuticals Inc. -12% -20.34% -12.19% -34.53% -49.28% -51.26%
Sophiris Bio Inc. 1.01% -6.51% -29.97% -45.97% 5.24% -11.45%

For the past year Sophiris Bio Inc. has weaker performance than Concert Pharmaceuticals Inc.

Summary

On 6 of the 10 factors Concert Pharmaceuticals Inc. beats Sophiris Bio Inc.

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. It discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including cystic fibrosis, autoimmune and inflammatory diseases, and central nervous systems disorders. The companyÂ’s clinical-stage product candidates include AVP-786, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with AlzheimerÂ’s disease; and CTP-656, which is in Phase 2 clinical trials to treat cystic fibrosis. It product candidates that have completed Phase 1 clinical trials comprise CTP-730 for use in the treatment of inflammation or cancer; JZP-386 for use in the treatment of excessive daytime sleepiness and cataplexy; and CTP-543 for use in the treatment of alopecia areata. The company has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. Concert Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.

Sophiris Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The companyÂ’s primary product candidate is PRX302, which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer. It has a strategic relationship with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of PRX302 and other products for the treatment of the symptoms of BPH, prostate cancer, prostatitis, or other diseases of the prostate; and license agreement with UVIC Industry Partnerships Inc. and The Johns Hopkins University with respect to the use of PRX302 for the development of therapeutics for the symptoms of BPH, prostate cancer, and other non-cancer diseases and conditions of the prostate. The company was formerly known as Protox Therapeutics Inc. and changed its name to Sophiris Bio, Inc. in April 2012. Sophiris Bio, Inc. was founded in 2002 and is based in La Jolla, California.